S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy THIS stock before Taiwan is attacked (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Buy THIS stock before Taiwan is attacked (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy THIS stock before Taiwan is attacked (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Buy THIS stock before Taiwan is attacked (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy THIS stock before Taiwan is attacked (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Buy THIS stock before Taiwan is attacked (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Buy THIS stock before Taiwan is attacked (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Buy THIS stock before Taiwan is attacked (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:PHVS

Pharvaris (PHVS) Stock Forecast, Price & News

$20.87
+0.60 (+2.96%)
(As of 09/29/2023 ET)
Compare
Today's Range
$19.86
$21.00
50-Day Range
$16.26
$21.40
52-Week Range
$1.77
$26.86
Volume
32,619 shs
Average Volume
43,407 shs
Market Capitalization
$664.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

Pharvaris MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.2% Upside
$23.00 Price Target
Short Interest
Healthy
0.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.88mentions of Pharvaris in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.46) to ($2.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

705th out of 972 stocks

Pharmaceutical Preparations Industry

328th out of 444 stocks


PHVS stock logo

About Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

PHVS Price History

PHVS Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Pharvaris N.V.
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Pharvaris To Present at the 18th German Allergy Congress
8 Analysts Have This to Say About Pharvaris
Morgan Stanley Upgrades Pharvaris (PHVS)
Analyst Expectations for Pharvaris's Future
Morgan Stanley Keeps Their Hold Rating on Pharvaris (PHVS)
Why Shares of Pharvaris N.V. Are Up Tuesday
5 Analysts Have This to Say About Pharvaris
See More Headlines
Receive PHVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.

PHVS Company Calendar

Last Earnings
8/07/2023
Today
9/30/2023
Next Earnings (Estimated)
12/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHVS
Fax
N/A
Employees
68
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+10.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-80,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.94 per share

Miscellaneous

Free Float
N/A
Market Cap
$664.50 million
Optionable
Not Optionable
Beta
-3.83
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Berndt Axel Edvard Modig CPA (Age 64)
    M.B.A., MBA, Co-Founder, CEO & Exec. Director
    Comp: $534.85k
  • Dr. Jochen Knolle Ph.D. (Age 73)
    Chief Scientific Officer & COO
  • Ms. Anna Nijdam M.Sc. (Age 42)
    R.A., Head of Strategic Fin. & Principal Accounting Officer
  • Ms. Joan Schmidt J.D. (Age 59)
    Chief Legal Officer
  • Dr. Peng Lu M.D. (Age 45)
    Ph.D., Chief Medical Officer
  • Dr. Anne A. Lesage Ph.D. (Age 62)
    Chief Early Devel. Officer
  • Dr. Morgan Conn Ph.D. (Age 54)
    Chief Bus. Officer
  • Mr. Wim Souverijns Ph.D. (Age 52)
    Chief Community Engagement & Commercial Officer
  • Maryann Cimino
    Director of Corp. Relations
  • Ms. Annick Deschoolmeester (Age 50)
    Chief HR Officer













PHVS Stock - Frequently Asked Questions

Should I buy or sell Pharvaris stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PHVS shares.
View PHVS analyst ratings
or view top-rated stocks.

What is Pharvaris' stock price forecast for 2023?

5 brokerages have issued 1 year target prices for Pharvaris' stock. Their PHVS share price forecasts range from $16.00 to $34.00. On average, they anticipate the company's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price.
View analysts price targets for PHVS
or view top-rated stocks among Wall Street analysts.

How have PHVS shares performed in 2023?

Pharvaris' stock was trading at $11.25 at the beginning of 2023. Since then, PHVS stock has increased by 85.5% and is now trading at $20.87.
View the best growth stocks for 2023 here
.

Are investors shorting Pharvaris?

Pharvaris saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 15,200 shares, a decrease of 22.1% from the August 31st total of 19,500 shares. Based on an average daily volume of 68,900 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the company's stock are short sold.
View Pharvaris' Short Interest
.

When is Pharvaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 14th 2023.
View our PHVS earnings forecast
.

How were Pharvaris' earnings last quarter?

Pharvaris (NASDAQ:PHVS) announced its quarterly earnings results on Monday, August, 7th. The company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.02.

When did Pharvaris IPO?

(PHVS) raised $126 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

What is Pharvaris' stock symbol?

Pharvaris trades on the NASDAQ under the ticker symbol "PHVS."

How do I buy shares of Pharvaris?

Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pharvaris' stock price today?

One share of PHVS stock can currently be purchased for approximately $20.87.

How much money does Pharvaris make?

Pharvaris (NASDAQ:PHVS) has a market capitalization of $664.50 million. The company earns $-80,420,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis.

How can I contact Pharvaris?

The official website for the company is www.pharvaris.com. The company can be reached via phone at 31-71-203-6410 or via email at sarah.mccabe@sternir.com.

This page (NASDAQ:PHVS) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -